Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious

Table 2 American College of Rheumatology core outcomes at baseline

	Etancercept plus methotrexate	Etanercept only	P value
SJC	10.3 ± 0.8	10.7 ± 1.1	Not significant
TJC	10.6 ± 1.0	11.2 ± 1.2	Not significant
HAQ	1.62 ± 0.08	1.86 ± 0.09	Not significant
Patient global	63.8 ± 3.1	72.2 ± 3.0	Not significant
Patient pain	65.1 ± 2.7	75.5 ± 3.0	< 0.02
Physician global	2.35 ± 0.10	2.49 ± 0.12	Not significant
ESR	32.6 ± 2.7	37.4 ± 3.4	Not significant

Values presented as mean ± standard error of the mean. Comparisons are by unpaired Student t test. ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire disability index; patient global, patient assessment of global health by 100 mm visual analogue scale; patient pain, patient assessment of pain by 100 mm visual analogue scale; physician global, physician's assessment of global disease activity by five-point scale (0–4); SJC, swollen joint count (based on 28 joints); TJC, tender joint count (based on 28 joints).

ISSN: 1478-6362